

Bibliographie

PSP de Coriolus versicolor

L'ensemble des articles ci-dessous est disponible par mail sur simple demande via la rubrique contact.

1. Arai, S., Milley, E. P., Lichtenberger, J., Savidge, C., Lawrence, J., & Côté, E. (2019). Metastatic cardiac hemangiosarcoma in a 6 year old wheaten terrier mix. *Veterinary Sciences*, 6(3), 65.
2. Brown, D. C., & Reetz, J. (2012). Single agent polysaccharopeptide delays metastases and improves survival in naturally occurring hemangiosarcoma. *Evidence-Based Complementary and Alternative Medicine*, 2012.
3. Cai, X., Pi, Y., Zhou, X., Tian, L., Qiao, S., & Lin, J. (2010). Hepatoma cell growth inhibition by inducing apoptosis with polysaccharide isolated from Turkey tail medicinal mushroom, *Trametes versicolor* (L.: Fr.) Lloyd (Aphylophoromycetidae). *International Journal of Medicinal Mushrooms*, 12(3).
4. Chaikin, P., & Welihozkiy, A. (2018). Hemangiosarcoma in a dog: Unusual presentation and increased survival using a complementary/holistic approach combined with metronomic chemotherapy. *Case reports in veterinary medicine*, 2018.
5. Chan, S. L., & Yeung, J. H. (2006). Effects of polysaccharide peptide (PSP) from *Coriolus versicolor* on the pharmacokinetics of cyclophosphamide in the rat and cytotoxicity in HepG2 cells. *Food and Chemical Toxicology*, 44(5), 689-694.
6. Chen, J., & Seviour, R. (2007). Medicinal importance of fungal β -(1 \rightarrow 3),(1 \rightarrow 6)-glucans. *Mycological research*, 111(6), 635-652.
7. Cheng, K. F., & Leung, P. C. (2008). General review of polysaccharopeptides (PSP) from *C. versicolor*: Pharmacological and clinical studies. *Cancer Therapy*, 6, 117-130.
8. Chu, K. K., Ho, S. S., & Chow, A. H. (2002). *Coriolus versicolor*: a medicinal mushroom with promising immunotherapeutic values. *The Journal of Clinical Pharmacology*, 42(9), 976-984.
9. Cui, J., & Chisti, Y. (2003). Polysaccharopeptides of *Coriolus versicolor*: physiological activity, uses, and production. *Biotechnology advances*, 21(2), 109-122.
10. Habtemariam, S. (2020). *Trametes versicolor* (Synn. *Coriolus versicolor*) Polysaccharides in Cancer Therapy: Targets and Efficacy. *Biomedicines*, 8(5), 135.
11. Ho, J. C. K., Konerding, M. A., Gaumann, A., Groth, M., & Liu, W. K. (2004). Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. *Life sciences*, 75(11), 1343-1356.
12. Ho, C. Y., Lau, C. B., Kim, C. F., Leung, K. N., Fung, K. P., Tse, T. F., ... & Chow, M. S. (2004). Differential effect of *Coriolus versicolor* (Yunzhi) extract on cytokine production by murine lymphocytes in vitro. *International immunopharmacology*, 4(12), 1549-1557.

13. Ho, C. Y., Kim, C. F., Leung, K. N., Kwok-Pui, F., Tse, T. F., Chan, H., & Bik-San Lau, C. (2005). Differential anti-tumor activity of coriolus versicolor (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. *Cancer biology & therapy*, 4(6), 638-644.
14. Ho, C. Y., Kim, C. F., Leung, K. N., Fung, K. P., Tse, T. F., Chan, H., & Lau, C. B. (2006). Coriolus versicolor (Yunzhi) extract attenuates growth of human leukemia xenografts and induces apoptosis through the mitochondrial pathway. *Oncology reports*, 16(3), 609.
15. Hsieh, T. C., Kunicki, J., Darzynkiewicz, Z., & Wu, J. M. (2002). Effects of extracts of Coriolus versicolor (I'm-Yunity™) on cell-cycle progression and expression of interleukins-1 β , -6, and -8 in Promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. *The Journal of Alternative & Complementary Medicine*, 8(5), 591-602.
16. Hsieh, T. C., Wu, P., Park, S., & Wu, J. M. (2006). Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity™(PSP). *BMC complementary and alternative medicine*, 6(1), 30.
17. Huang, R., Zhang, J., Liu, Y., Hao, Y., Yang, C., Wu, K., ... & Wu, C. (2013). Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide. *Molecular medicine reports*, 8(2), 669-675.
18. Hui, K. P. Y., Sit, W. H., & Wan, J. M. F. (2005). Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells. *Oncology reports*, 14(1), 145-155.
19. Jian, X., Huang, L., Zhou, Y., & Wang, M. M. (1999). Subchronic toxicity test of polysaccharopeptide of Yun Zhi (PSP). In *International Symposium on Traditional Chinese Medicine and Cancer: Development and Clinical Validation—Advances Research in PSP*. Hong Kong Association for Health Care Ltd (pp. 272-284).
20. Jin, T. Y. (1999). Toxicological research on Yun Zhi polysaccharopeptide (PSP). In *International Symposium on Traditional Chinese Medicine and Cancer: Development and Clinical Validation—Advances Research in PSP*. Hong Kong Association for Health Care Ltd (pp. 76-79).
21. Kenyon-Dove, K. (2003). Observational non-controlled study of the use of Coriolus versicolor supplementation in 30 cancer patients. *Mycology News*, 1(8), 2-4.
22. Kidd, P. M. (2000). The use of mushroom glucans and proteoglycans in cancer treatment. *Alternative Medicine Review*, 5(1), 4-27.
23. Kowalczyńska, M., Piotrowski, J., Jędrzejewski, T., & Kozak, W. (2016). Polysaccharide peptides from Coriolus versicolor exert differential immunomodulatory effects on blood lymphocytes and breast cancer cell line MCF-7 in vitro. *Immunology letters*, 174, 37-44.
24. Lam, C. S., Cheng, L. P., Zhou, L. M., Cheung, Y. T., & Zuo, Z. (2020). Herb–drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. *Chinese medicine*, 15(1), 1-18.

25. Lau, C. B. S., Ho, C. Y., Kim, C. F., Leung, K. N., Fung, K. P., Tse, T. F., ... & Chow, M. S. S. (2004). Cytotoxic activities of *Coriolus versicolor* (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. *Life Sciences*, 75(7), 797-808.
26. Lee, C. L., (2005). Immunomodulatory properties of polysaccharopeptide derived from *Coriolus versicolor* and its combined effect with Cyclosporine a inactivated human Tcells. HKU Theses Online (HKUTO).
27. Lee, C. L., Yang, X., & Wan, J. M. F. (2006). The culture duration affects the immunomodulatory and anticancer effect of polysaccharopeptide derived from *Coriolus versicolor*. *Enzyme and Microbial Technology*, 38(1), 14-21.
28. Liu, J. X., & Zhou, J. Y. (1993, November). Phase II clinical trial for PSP capsules. In *PSP International Symposium* (pp. 183-208). Fudan University Press Hong Kong.
29. Luo, K. W., Yue, G. G. L., Ko, C. H., Lee, J. K. M., Gao, S., Li, L. F., ... & Bik-San Lau, C. (2014). In vivo and in vitro anti-tumor and anti-metastasis effects of *Coriolus versicolor* aqueous extract on mouse mammary 4T1 carcinoma. *Phytomedicine*, 21(8), 1078-1087.
30. LY Eliza, W., K Fai, C., & P Chung, L. (2012). Efficacy of Yun Zhi (*Coriolus versicolor*) on survival in cancer patients: systematic review and meta-analysis. *Recent patents on inflammation & allergy drug discovery*, 6(1), 78-87.
31. Mao, X. W., Green, L. M., & Gridley, D. S. (2001). Evaluation of polysaccharopeptide effects against C6 glioma in combination with radiation. *Oncology*, 61(3), 243-253.
32. Migita, T., Sato, E., Saito, K., Mizoi, T., Shiiba, K. I., Matsuno, S., ... & Ohtani, H. (1999). Differing expression of MMPs-1 and-9 and urokinase receptor between diffuse-and intestinal-type gastric carcinoma. *International journal of cancer*, 84(1), 74-79.
33. Ng, T. B. (1998). A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom *Coriolus versicolor* (Basidiomycetes: Polyporaceae). *General Pharmacology: The Vascular System*, 30(1), 1-4.
34. Nicandro, J. P. A., Tsourounis, C., Frassetto, L., & Guglielmo, B. J. (2007). In vivo Effect of l'm-Yunity™ on Hepatic Cytochrome P450 3A4. *Journal of herbal pharmacotherapy*, 7(1), 39-56.
35. Patel, S., & Goyal, A. (2012). Recent developments in mushrooms as anti-cancer therapeutics: a review. *3 Biotech*, 2(1), 1-15.
36. Saleh, M. H., Rashedi, I., & Keating, A. (2017). Immunomodulatory properties of *Coriolus versicolor*: The role of polysaccharopeptide. *Frontiers in immunology*, 8, 1087.
37. Sekhon, B. K., Sze, D. M. Y., Chan, W. K., Fan, K., Li, G. Q., Moore, D. E., & Roubin, R. H. (2013). PSP activates monocytes in resting human peripheral blood mononuclear cells: Immunomodulatory implications for cancer treatment. *Food chemistry*, 138(4), 2201-2209.
38. Shi, J. H., Chart, T., & Lian, Z. R. (1993, November). The clinical research of the effect of PSP on the immunological function of stomach cancer patients during operation and chemotherapy. In Q. Yang (Ed.), *Proceedings of the PSP International Symposium* (pp. 232-240). Fudan University Press.

39. Shimura, S., Yang, G., Ebara, S., Wheeler, T. M., Frolov, A., & Thompson, T. C. (2000). Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. *Cancer research*, 60(20), 5857-5861.
40. Torkelson, C. J., Sweet, E., Martzen, M. R., Sasagawa, M., Wenner, C. A., Gay, J., ... & Standish, L. J. (2012). Phase 1 clinical trial of Trametes versicolor in women with breast cancer. *ISRN oncology*, 2012.
41. Tsang, K. W., Lam, C. L., Yan, C., Mak, J. C., Ooi, G. C., Ho, J. C., ... & Lam, W. K. (2003). Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. *Respiratory medicine*, 97(6), 618-624.
42. Wan, J. M. F., Sit, W. H., & Louie, J. C. Y. (2008). Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-
43. 30. *International journal of oncology*, 32(3), 689-699.
44. Xiang, D., Sharma, V. R., Freter, C. E., & Yan, J. (2012). Anti-tumor monoclonal antibodies in conjunction with β -glucans: a novel anti-cancer immunotherapy. *Current medicinal chemistry*, 19(25), 4298-4305.
45. YAN, W., ZHU, Y. P., & SUN, T. W. (2000). The Effect of PSP on Immune Function and Living
46. Quality in Patients Receiving Chemotherapy for Gynecological. Malignancies [J]. *JOURNAL OF*
47. SHANGHAI TEACHERS UNIVERSITY, 2, 013.
48. Yang, Q. Y., Hu, Y. J., Li, X. Y., Yang, J. C., Liu, J. X., Liu, T. F., ... & Liao, M. L. (1993). A new biological response modifier substance—PSP. In *PSP international symposium* (pp. 56-72). Fudan University Press. China.
49. Yang, Q. Y. (1999). Yun Zhi polysaccharopeptide (PSP) and the general aspects of its research. *Advanced Research in PSP*, 29-38.
50. Yang, X., Sit, W. H., Chan, D. K. O., & Wan, J. M. F. (2005). The cell death process of the anticancer agent polysaccharide-peptide (PSP) in human promyelocytic leukemic HL-60 cells. *Oncology reports*, 13(6), 1201-1210.
51. Zhou, X., Jiang, H., Lin, J., & Tang, K. (2007). Cytotoxic activities of Coriolus versicolor
52. (Yunzhi) extracts on human liver cancer and breast cancer cell line. *African Journal of*
53. *Biotechnology*, 6(15).

Ils parlent de nous...

L'ESSENTIEL

Floch F. (7 au 13 novembre 2019), « Prise en charge d'un h moabdomen, Suivi clinique d'un h mangiosarcome spl nique », *l'Essentiel*, n 542, p.24-25.

Lafon M (23 au 27 septembre 2017), « Un extrait de champignon int ressant dans la gestion de l'animal cancéreux », *la D p che V t rinaire*, n 1406, p.21.

Sim on C. (12 au 25 octobre 2017), « Coriolus versicolor, la mycoth rapie au service des v t rinaires », *l'Essentiel*, n 461/461, p.34.

Bibliographie

Hémangiosarcomes

- 1'. Brown, D. C., & Reetz, J. (2012). Single agent polysaccharopeptide delays metastases and improves survival in naturally occurring hemangiosarcoma. *Evidence-Based Complementary and Alternative Medicine*, 2012.
- 2'. Finotello, R., Stefanello, D., Zini, E., & Marconato, L. (2017). Comparison of doxorubicin–cyclophosphamide with doxorubicin–dacarbazine for the adjuvant treatment of canine hemangiosarcoma. *Veterinary and Comparative Oncology*, 15(1), 25-35.
- 3'. Gardner, H. L., London, C. A., Portela, R. A., Nguyen, S., Rosenberg, M. P., Klein, M. K., ... & Crawford-Jakubiak, M. (2015). Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. *BMC Veterinary Research*, 11(1), 1-9.
- 4'. Hammer, A. S., Couto, C. G., Filppi, J., Getzy, D., & Shank, K. (1991). Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. *Journal of Veterinary Internal Medicine*, 5(3), 160-166.
- 5'. Kahn, S. A., Mullin, C. M., de Lorimier, L. P., Burgess, K. E., Risbon, R. E., Fred III, R. M., ... & Clifford, C. A. (2013). Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. *The Canadian Veterinary Journal*, 54(3), 237.
- 6'. Kim, S. E., Liptak, J. M., Gall, T. T., Monteith, G. J., & Woods, J. P. (2007). Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997–2004). *Journal of the American Veterinary Medical Association*, 231(10), 1550-1557.
- 7'. Lana, S., U'ren, L., Plaza, S., Elmslie, R., Gustafson, D., Morley, P., & Dow, S. (2007). Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. *Journal of Veterinary Internal Medicine*, 21(4), 764-769.
- 8'. Moore, A. S., Rassnick, K. M., & Frimberger, A. E. (2017). Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011–2014). *Journal of the American Veterinary Medical Association*, 251(5), 559-565.
- 9'. Ogilvie, G. K., Powers, B. E., Mallinckrodt, C. H., & Withrow, S. J. (1996). Surgery and doxorubicin in dogs with hemangiosarcoma. *Journal of Veterinary Internal Medicine*, 10(6), 379-384.
- 10'. Payne, S. E., Rassnick, K. M., Northrup, N. C., Kristal, O., Chretin, J. D., Cotter, S. M., ... & Moore, A. S. (2003). Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin. *Veterinary and Comparative Oncology*, 1(4), 171-179.

- 11'. Prymak, C. A. R. O. L. I. N. E., McKee, L. J., Goldschmidt, M. H., & Glickman, L. T. (1988). Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). *Journal of the American Veterinary Medical Association*, 193(6), 706-712.
- 12'. Rassnick, K. M., Frimberger, A. E., Wood, C. A., Williams, L. E., Cotter, S. M., & Moore, A. S. (2000). Evaluation of ifosfamide for treatment of various canine neoplasms. *Journal of Veterinary Internal Medicine*, 14(3), 271-276.
- 13'. Sorenmo, K. U., Jeglum, K. A., & Helfand, S. C. (1993). Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. *Journal of Veterinary Internal Medicine*, 7(6), 370-376.
- 14'. U'Ren, L. W., Biller, B. J., Elmslie, R. E., Thamm, D. H., & Dow, S. W. (2007). Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. *Journal of Veterinary Internal Medicine*, 21(1), 113-120.
- 15'. Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Kisseberth, W. C., ... & Rodriguez, C. O. (1995). Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. *Clinical Cancer Research*, 1(10), 1165-1170.
- 16'. Wood, C. A., Moore, A. S., Gliatto, J. M., Ablin, L. A., Berg, R. J., & Rand, W. M. (1998). Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). *Journal of the American Animal Hospital Association*, 34(5), 417-421.